Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (3217)	4/14/2013 10:24:06 PM
From: richardred	Read Replies (1) \| Respond to of 7239

Still waiting for some PTIE news. Maybe this is what the FDA is waiting for? SNIP>Generic OxyContin Pains the FDA The first patent on OxyContin expires Tuesday, a milestone in the history of one of the most powerful and abused painkillers on the market. But it could be quite some time before generic versions of the drug are available. Generic-drug makers have lined up to make their own versions of the medication, which has become synonymous with painkiller abuse. But first, they must wait for the Food and Drug Administration to decide whether they may produce the original version of OxyContin—the one losing patent protection—or whether they may make only newer versions designed to impede abuse, which won't come off patent for several more years. online.wsj.com